Mark R. Bamforth is an entrepreneur, investor and mentor in life sciences. Mark has founded, built, and sold three contract development and manufacturing organisations (CDMOs) over the last 12 years. His first company, Gallus Biopharmaceuticals, focused on monoclonal antibodies. His second company, Brammer Bio produced viral vectors for gene therapies. His third company. ArrantaBio, produced advanced therapies, including microbiome therapeutics. Previously, Bamforth spent 22 years at Genzyme, latterly running global manufacturing operations. His career began as a petroleum engineer with Britoil, then as a chemical engineer with Whitbread. Bamforth serves on the boards of Continuus Pharma, EnteroBiotix, Inceptor Bio, Pneumagen, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.